Therapeutic monitoring of serum digoxin for patients with heart failure using a rapid LC-MS/MS method

Clinical Biochemistry

Volumn 43, Issue 3, 2010, Pages 307-313

  Li, Shuijun ^a,b   Liu, Gangyi ^a   Jia, Jingying ^a   Miao, Yi ^a   Gu, Shuiming ^a   Miao, Peizhi ^a   Shi, Xueying ^a   Wang, Yiping ^b   Yu, Chen ^a  

^a SHANGHAI XUHUI CENTRAL HOSPITAL   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Digoxin; Heart failure; Human serum; LC MS MS; Liquid liquid extraction; Therapeutic drug monitoring

Indexed keywords

DIGOXIN; TERT BUTYL METHYL ETHER;

ARTICLE; BLOOD SAMPLING; DIGOXIN BLOOD LEVEL; DRUG MONITORING; ELECTROSPRAY MASS SPECTROMETRY; HEART FAILURE; HUMAN; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; PRIORITY JOURNAL; QUALITY CONTROL; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; DIGOXIN; HEART FAILURE; HUMANS; MOLECULAR STRUCTURE; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 74249094449     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.09.025     Document Type: Article

References (25)

1. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N. Engl. J. Med. 336 (1997) 525-533
2. Ahmed A., Waagstein F., Pitt B., et al. Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am. J. Cardiol. 103 (2009) 82-87
3. Ahmed A., Rich M.W., Love T.E., et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur. Heart J. 27 (2006) 178-186
4. Ahmed A. Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. J. Gerontol. A Biol. Sci. Med. Sci. 62 (2007) 323-329
5. Adams K.F., Patterson J.H., Gattis W.A., et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J. Am. Coll. Cardiol. 46 (2005) 497-504
6. Rathore S.S., Curtis J.P., Wang Y., et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 (2003) 871-878
7. Terra S.G., Washam J.B., Dunham G.D., et al. Therapeutic range of digoxin's efficacy in heart failure: what is the evidence?. Pharmacotherapy 19 (1999) 1123-1126
8. Bauman J.L., DiDomenico R.J., Viana M., et al. A method of determining the dose of digoxin for heart failure in the modern era. Arch. Intern. Med. 166 (2006) 2539-2545
9. Ellington C., Grgurinovich N., Miners J.O., et al. Quality of requests for serum digoxin concentrations: experience from an Australian regional health service. Br. J. Clin. Pharmacol. 63 (2007) 623-627
10. Sidwell A., Barclay M., Begg E., et al. Digoxin therapeutic drug monitoring: an audit and review. N. Z. Med. J. 116 (2003) U708
11. Steimer W., Muller C., and Eber B. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids. Clin. Chem. 48 (2002) 507-516
12. Jones T.E., and Morris R.G. Discordant results from "real-world" patient samples assayed for digoxin. Ann. Pharmacother. 42 (2008) 1797-1803
13. Reyes M.A., Actor J.K., Risin S.A., et al. Effect of Chinese medicines Chan Su and Lu-Shen-Wan on serum digoxin measurement by Digoxin III, a new digoxin immunoassay. Ther. Drug Monit. 30 (2008) 95-99
14. Dasgupta A. Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St. John's wort. Ther. Drug Monit. 30 (2008) 212-217
15. Kirby B.J., Kalhorn T., Hebert M., et al. Sensitive and specific LC-MS assay for quantification of digoxin in human plasma and urine. Biomed. Chromatogr. 22 (2008) 712-718
16. Hashimoto Y., Shibakawa K., Nakade S., et al. Validation and application of a 96-well format solid-phase extraction and liquid chromatography-tandem mass spectrometry method for the quantitation of digoxin in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 869 (2008) 126-132
17. Smalley J., Marino A.M., Xin B., et al. Development of a quantitative LC-MS/MS analytical method coupled with turbulent flow chromatography for digoxin for the in vitro P-gp inhibition assay. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 854 (2007) 260-267
18. Mitamura K., Horikawa A., Yamane Y., et al. Determination of digoxin in human serum using stable isotope dilution liquid chromatography/electrospray ionization-tandem mass spectrometry. Biol. Pharm. Bull. 30 (2007) 1653-1656
19. Kaiser P., Akerboom T., Wood W.G., et al. A novel LC-IDMS/MS method for the determination of the cardiac glycosides digoxin and digitoxin using caesium adducts. Clin. Lab. 52 (2006) 37-42
20. Yao M., Zhang H., Chong S., et al. A rapid and sensitive LC/MS/MS assay for quantitative determination of digoxin in rat plasma. J. Pharm. Biomed. Anal. 32 (2003) 1189-1197
21. Tracqui A., Kintz P., Ludes B., et al. High-performance liquid chromatography-ionspray mass spectrometry for the specific determination of digoxin and some related cardiac glycosides in human plasma. J. Chromatogr. B Biomed. Sci. Appl. 692 (1997) 101-109
22. U.S. Food and Drug Administration, Bioanalytical Method Validation., U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, May 2001.
23. Meija J., and Mester Z. Paradigms in isotope dilution mass spectrometry for elemental speciation analysis. Anal. Chim. Acta 607 (2008) 115-125
24. Vogeser M., and Parhofer K.G. Liquid chromatography tandem-mass spectrometry (LC-MS/MS)-technique and applications in endocrinology. Exp. Clin. Endocrinol. Diabetes 115 (2007) 559-570
25. Bowers G.N., Fassett J.D., and Et W.h.i.t.e. Isotope dilution mass spectrometry and the National Reference System. Anal. Chem. 65 (1993) 475R-479R